Blog
About

0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Epidemiology of Hypercholesterolemia and European Management Guidelines

      Cardiology

      S. Karger AG

      Hypercholesterolemia, Atherosclerosis, European Atherosclerosis Society

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Some people may argue that one cannot, in a strict sense of the word, speak about the ‘epidemiology of hypercholesterolemia’ Epidemiology is a systematic description of the distribution of diseases and causally related factors, and hypercholesterolemia (disregarding the choice of cut-off points for the diagnosis) cannot be considered a disease. Cholesterol, on the other hand, is causally related to atherosclerosis, and a more proper title of this paper might have been ‘The Distribution of Total Cholesterol and the European Guidelines’. The European guidelines refer to the Policy Statement of the European Atherosclerosis Society on the prevention of coronary heart disease (CHD). This document emphasizes the need for a complementary approach directed to CHD-prone populations as a whole and individuals at particular risk. It includes improved nutrition, avoidance of smoking, BP reduction, and promotion of suitable exercise. The responsibility for such measures is laid both upon governmental and supranational agencies.To provide care for individuals at particular risk for CHD, case finding requires that risk factor assessment, including blood lipids and BP, be included in full medical examinations. In Europe total cholesterol levels above 5.2 mmol/l (200 mg/dl) deserve consideration, but it is considered that for the part of the population with levels between 5.2 and 6.5 mmol/l, dietary advices are appropriate in addition to the correction of other risk factors. In the European area, 40–48% of the men aged 40–59 years and 39–54% of the women will be between these limits. In the northern part of Europe, 41% of the men and 49% of the women of this age group have total cholesterol levels above 6.5 mmol/l (250 mg/dl). In the southern part the situation is somewhat brighter, with about 25% of the population exceeding this limit, a fact that is reflected in the considerable north-south gradient with regard to CHD in Europe. It is obvious that the very ambitious goals set forward by the European Atherosclerosis Society can only be achieved if the European countries on a mutual basis recognize the need for nutritional changes and the total avoidance of cigarette smoking. An individual approach aiming at about 50% of the healthy population is inconceivable and must be combined with public health policy measures.

          Related collections

          Author and article information

          Journal
          CRD
          Cardiology
          10.1159/issn.0008-6312
          Cardiology
          S. Karger AG
          978-3-8055-5278-3
          978-3-318-00092-4
          0008-6312
          1421-9751
          1990
          1990
          12 November 2008
          : 77
          : Suppl 4
          : 2-7
          Affiliations
          National Health Screening Service, Oslo, Norway
          Article
          174677 Cardiology 1990;77:2–7
          10.1159/000174677
          2073668
          © 1990 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 6
          Categories
          HMG CoA Reductase Inhibitors: New Horizons in the Management of Hypercholesterolemia

          Comments

          Comment on this article